Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs SLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VNDA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

VNDA Overall Winner 6-Pillar Tally: VNDA 3 – 2 SLN (1 Tie) Matrix Metrics: VNDA 5 – 5 SLN

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas SLN carries 46.9/100 (HOLD) at $19.82 (N/M Forward P/E, -10475.6% operating margin).

  • Growth vs. Quality Trade-Off: VNDA earns the overall head-to-head edge with a stronger Unified Composite Score (49.0/100 HOLD vs. SLN 46.9/100 HOLD) and 1.25β · 61% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs SLN
VNDA NASDAQ Head-to-Head Winner
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.82
-0.08% 1D
Market Cap $1.2B
TTM Revenue $615,000
Forward P/E N/M
Beta / 30D Vol 1.92β · 4% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 24.0 Fund 34.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (18.5% over 20 days), RSI 77
RSI-14: 77.3 · SMA20: $19.75 · SMA50: $14.77

6-Pillar Scorecard Institutional Category Breakdown (VNDA 3 – 2 SLN)

Columns: Metric · VNDA · SLN
1. Valuation Multiples VNDA
Forward P/E 103.1x N/M
Trailing P/E 103.1x N/M
PEG Ratio 2.23x N/M
EV / Revenue 0.9x N/M
2. Growth & Scale SLN
Revenue Growth (YoY) +24.1% +197.2%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M $615,000
Market Cap $238.9M $1.2B
3. Profitability & Quality VNDA
Gross Margin 93.6% 85.9%
Operating Margin -77.6% -10475.6%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -90.4%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$64M EBITDA
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $0.81 Book/Sh · -90.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 163.3% (75th %ile) 55.4% (50th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (5) vs SLN (5)
Institutional Metric VNDA SLN Criterion Row Edge
Market Capitalization
Scale
$238.9M $1.2B Larger Scale SLN
Trailing P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Forward P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% +197.2% Higher Growth SLN
Operating Margin (TTM)
Profitability
-77.6% -10475.6% Higher Margin VNDA
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin SLN
Return on Equity (ROE)
Capital Efficiency
-82.5% -90.4% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 100% ($4–$20) Stronger Trend SLN
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.92β · 4% Vol Lower Realized Risk SLN
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 46.9 / 100 (HOLD) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$229M $615,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 85.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$64M EBITDA ($0.81 Book/Sh · -90.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLN +134.11 pp
VNDA: -5.83% · SLN: +128.28%
3M Horizon SLN +70.77 pp
VNDA: -30.24% · SLN: +40.53%
6M Horizon SLN +255.64 pp
VNDA: -37.58% · SLN: +218.06%
1Y Horizon SLN +198.9 pp
VNDA: -12.56% · SLN: +186.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VNDA vs SLN. Trailing 12-month operating profitability (VNDA -77.6% vs SLN -10475.6%) and valuation multiples (VNDA 103.1x vs SLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VNDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$229M
Gross Margin93.6%
Op. Margin-77.6%
ROE / Fwd P/E-82.5% · 103.1x
SLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$615,000
Gross Margin85.9%
Op. Margin-10475.6%
ROE / Fwd P/E-90.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SLN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -10475.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs SLN Key Questions & Quantitative Answers

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas SLN carries 46.9/100 (HOLD) at $19.82 (N/M Forward P/E, -10475.6% operating margin). Growth vs. Quality Trade-Off: VNDA earns the overall head-to-head edge with a stronger Unified Composite Score (49.0/100 HOLD vs. SLN 46.9/100 HOLD) and 1.25β · 61% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SLN leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with SLN at +197.2% YoY revenue growth and +0.0% YoY earnings growth on $615,000 TTM revenue (85.9% gross margin, -10475.6% operating margin). On trailing 12-month operating scale, VNDA generates $229M in USD-normalized revenue versus $615,000 for SLN. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLN.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus SLN (-90.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.